Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma
Retrospective analysis reveals poor progression-free survival in relapsed multiple myeloma with IEC-HS after ide-cel and cilta-cel therapies.
Key Points
This research aims to analyze the real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in multiple myeloma patients.
Retrospective multi-institutional analysis from 15 centers
Included patients with relapsed/refractory multiple myeloma
Defined IEC-HS based on diagnostic criteria
Utilized Kaplan-Meier and logistic regression analyses
74 out of 1502 patients diagnosed with IEC-HS (4.9%)
Median progression-free survival of 6.5 months with cilta-cel and 8.9 months with ide-cel for IEC-HS
Increased rates of cytopenias, renal insufficiency, and pulmonary involvement observed in IEC-HS patients
IEC-HS associated with poorer overall survival (median OS of 9.6 months for cilta-cel)